Molecular structure of (R)-Lisofylline, CAS Number: 100324-81-0
(R)-Lisofylline (CAS 100324-81-0)
Alternate Names:
3,7-Dihydro-1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-1H-purine-2,6-dione; CT 1501R; Lisophylline; ProTec
Application:
(R)-Lisofylline is an immunomodulator and metabolite of Pentoxifyline, it inhibits phosphatidic acid production
CAS Number:
100324-81-0
Molecular Weight:
280.32
Molecular Formula:
C13H20N4O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
(R)-Lisofylline is an immunomodulator and a major metabolite of Pentoxifylline and Methylxanthine. (R)-Lisofylline inhibits production of phosphatidic acid during the inflammatory response. (R)-Lisofylline, a synthetic drug with both anti-inflammatory and anti-oxidative properties, has been extensively researched in the last decade. It is derived from the natural compound lisofylline, which is a glycoside of lysine, an amino acid. The drug′s potential in treating various inflammatory and oxidative-mediated diseases has been thoroughly investigated. Specifically, its capacity to mitigate inflammation and oxidative stress in the brain, heart, and other organs has been studied.
(R)-Lisofylline (CAS 100324-81-0) References
- Caffeine analogs: biomedical impact. | Daly, JW. 2007. Cell Mol Life Sci. 64: 2153-69. PMID: 17514358
- The serum metabolomic study of intervention effects of the traditional Chinese medicine Shexiang Baoxin Pill and a multi-component medicine polypill in the treatment of myocardial infarction in rats. | Xiang, L., et al. 2012. Mol Biosyst. 8: 2434-42. PMID: 22791014
- Remote ester group leads to efficient kinetic resolution of racemic aliphatic alcohols via asymmetric hydrogenation. | Yang, XH., et al. 2014. J Am Chem Soc. 136: 17426-9. PMID: 25437900
- Boron-Catalyzed Regioselective Deoxygenation of Terminal 1,2-Diols to 2-Alkanols Enabled by the Strategic Formation of a Cyclic Siloxane Intermediate. | Drosos, N. and Morandi, B. 2015. Angew Chem Int Ed Engl. 54: 8814-8. PMID: 26089307
- Active Site Crowding of Cytochrome P450 3A4 as a Strategy To Alter Its Selectivity. | Schiavini, P., et al. 2017. Chembiochem. 18: 248-252. PMID: 27897366
- Application of metabolomics for unveiling the therapeutic role of traditional Chinese medicine in metabolic diseases. | Wu, G., et al. 2019. J Ethnopharmacol. 242: 112057. PMID: 31279867
- Quantitative Evaluation of the Contribution of Each Aldo-Keto Reductase and Short-Chain Dehydrogenase/Reductase Isoform to Reduction Reactions of Compounds Containing a Ketone Group in the Human Liver. | Ichida, H., et al. 2023. Drug Metab Dispos. 51: 17-28. PMID: 36310032
- Highly Efficient Asymmetric Hydrogenation Catalyzed by Iridium Complexes with Tridentate Chiral Spiro Aminophosphine Ligands. | Yang, F., et al. 2023. Acc Chem Res. 56: 332-349. PMID: 36689780
- Chemoenzymatic enantioselective and stereo-convergent syntheses of lisofylline enantiomers via lipase-catalyzed kinetic resolution and optical inversion approach | Borowiecki, P., Zdun, B., & Dranka, M. 2021. Molecular Catalysis. 504: 111451.
- Chemoenzymatic deracemization of lisofylline catalyzed by a (laccase/TEMPO)-alcohol dehydrogenase system | Borowiecki, P., Rudzka, A., Reiter, T., & Kroutil, W. 2022. Catalysis Science & Technology. 12(13): 4312-4324.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
(R)-Lisofylline, 2 mg | sc-208243 | 2 mg | $286.00 |